Helical intravitreal triamcinolone acetonide implant: A 6-month surgical feasibility study in rabbits

Ophthalmic Surgery Lasers and Imaging

Volumn 40, Issue 2, 2009, Pages 160-168

  Mello Filho, Paulo A A ^a,b,c   Guven, Dilek ^a,d   Beeley, Nathan R F ^a,e   De Juan Jr , Eugene ^a,f   Erickson, Signe R ^a,g  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c CAPES ^*  (Brazil)

^d SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^e Vistakon   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SurModics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE ACETONIDE; GLUCOCORTICOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATARACT; CONTROLLED STUDY; EYE EXAMINATION; INTRAOCULAR PRESSURE; LENS IMPLANT; NONHUMAN; PRIORITY JOURNAL; SCLEROTOMY; SURGICAL TECHNIQUE; SUSTAINED RELEASE FORMULATION; VITREOUS BODY; VITREOUS HEMORRHAGE; ANIMAL; DRUG EFFECT; DRUG IMPLANT; FEASIBILITY STUDY; FOLLOW UP; GLAUCOMA SURGERY; METHODOLOGY; PATHOLOGY; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; RABBIT; RETINA;

ANIMALS; DRUG IMPLANTS; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; INTRAOPERATIVE COMPLICATIONS; POSTOPERATIVE COMPLICATIONS; RABBITS; RETINA; SCLEROSTOMY; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 64849083842     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/15428877-20090301-17     Document Type: Article

References (32)

1. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res. 2005;24:587-611. (Pubitemid 40949559)
2. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001;108:765-772. (Pubitemid 32238474)
3. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2001;131:468-471. (Pubitemid 32273433)
4. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001;132:425-427. (Pubitemid 32768624)
5. Benhamou N, Massin P, Haouchine B, Audren F, Tadayoni R, Gaudric A. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol. 2003;135:246-249. (Pubitemid 36151814)
6. Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol. 2003;136:419-425. (Pubitemid 37101237)
7. Scott IU, Flynn HW Jr, Rosenfeld PJ. Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema. Am J Ophthalmol. 2003;136:737-739. (Pubitemid 37153193)
8. Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol. 2001;119:1380-1383. (Pubitemid 32994890)
9. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina. 2000;20:244-250. (Pubitemid 30436775)
10. Rechtman E, Allen VD, Danis RP, Pratt LM, Harris A, Speicher MA. Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am J Ophthalmol. 2003;136:739-741. (Pubitemid 37153194)
11. Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems: recent advances. Prog Retin Eye Res. 1998;17:33-58. (Pubitemid 28040752)
12. Peyman GA, Ganiban GJ. Delivery systems for intraocular routes. Adv Drug Deliv Rev. 1995;16:107-123.
13. Le Bourlais CA, Treupel-Acar L, Rhodes CT, Sado PA, Leverge R. New ophthalmic drug delivery systems. Drug Dev Ind Pharm. 1995;21:19-59.
14. Peyman GA, Ganiban GJ. Delivery systems for intraocular routes. Adv Drug Deliv Rev. 1995;16:107.
15. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci. 2000;41:961-964. (Pubitemid 30187528)
16. Holekamp NM, Thomas MA, Pearson A. The safety profile of long-term, high-dose intraocular corticosteroid delivery. Am J Ophthalmol. 2005;139:421-428. (Pubitemid 40379067)
17. Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 2005;112:1192-1198. (Pubitemid 40916923)
18. Bourges JL, Bloquel C, Thomas A, et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev. 2006;58:1182-1202.
19. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309-317. (Pubitemid 46425557)
20. The Association for Research in Vision and Ophthalmology. Statement for the Use of Animals in Ophthalmic and Visual Research [text on the Internet]. Rockville, MD: Author; 2000 [cited 2007 Feb 02]. Available from: http://www.arvo.org/eweb/dynamicpage.aspx?site=arvo2&webcode= AnimalsResearch.
21. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol. 1985;103:1567-1569. (Pubitemid 15240750)
22. Henderer JD, Rapuano CJ. Ocular pharmacology. In: Goodman LS, Gilman A, Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed. New York: McGraw-Hill; 2006:1707-1737.
23. Sanborn GE, Anand R, Torti RE, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device. Arch Ophthalmol. 1992;110:188-195.
24. Smith TJ, Pearson PA, Blandford DL, et al. Intravitreal sustained-release ganciclovir. Arch Ophthalmol. 1992;110:255-258.
25. Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med. 1997;337:83-90. (Pubitemid 27284393)
26. Jaffe GJ, Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina. 2000;20:402-403.
27. Cheng CK, Berger AS, Pearson PA, Ashton P, Jaffe GJ. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest Ophthalmol Vis Sci. 1995;36:442-453.
28. Bausch & Lomb Pharmaceuticals. Retisert: Fluocinolone Acetonide Intravitreal Implant [text on the Internet]. Rochester, NY: Author; 2005 [cited 2007 Jan 30]. Available from: http://www.retisert.com/prescribing-information. pdf.
29. Jaffe GJ, Ben-Nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024-2033.
30. Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci. 2000;41:3569-3575.
31. Taguri AH, Dhillon B, Wharton SB, Kamal A. Foreign body reaction with delayed extrusion of ganciclovir implant in a patient with immune recovery vitritis syndrome. Am J Ophthalmol. 2002;133:147-149. (Pubitemid 34076519)
32. Goyal NA, Cohen JA, Packo KH. Delayed extrusion of ganciclovir implant. Retina. 2006;26:829-830. (Pubitemid 44386110)